VALUE-Dx is an IMI2-funded project whose focus is the value of diagnostics to combat antimicrobial resistance (AMR) by optimising antibiotic use. Coordinated by the University of Antwerp, the vision of VALUE-Dx is to transform clinical practice, improve patient outcomes, and combat AMR through the widespread use of clinical and cost-effective innovative diagnostics strategies in order to achieve more personalised, evidence-based antibiotic prescription and use in community care settings. The purpose of VALUE-Dx is to facilitate and accelerate the rigorous assessment and implementation of new diagnostic technologies into healthcare settings, by establishing the infrastructure, methods, processes, and approaches needed to understand, evaluate, assess, and demonstrate the multi-faceted value of diagnostics and overcome the associated barriers to their widespread adoption and use.
Penta is the paediatric partner in VALUE-Dx, and will leverage sites from the PED-MERMAIDS trial to participate in a point-prevalence study and a clinical study within VALUE-Dx to demonstrate the value of diagnostics in the optimal management of community-acquired acute respiratory tract infections (CA-ARTIs).
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755.
The Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.